Global Central Nervous System Therapeutics Market by Diseases (Cancer, Degenerative Diseases, Infectious Diseases), Drug Class (Analgesics, Anesthetics, Anti-Epileptics), End-Users - Forecast 2024-2030- Product Image

Sale

Global Central Nervous System Therapeutics Market by Diseases (Cancer, Degenerative Diseases, Infectious Diseases), Drug Class (Analgesics, Anesthetics, Anti-Epileptics), End-Users - Forecast 2024-2030

Report
185 Pages
March 2024
Region: Global
360iResearch™
ID: 5665844

UP TO €846EUR$875USD£725GBP OFF until Dec 31^st 2024

The Central Nervous System Therapeutics Market size was estimated at USD 70.17 billion in 2023, USD 76.41 billion in 2024, and is expected to grow at a CAGR of 9.37% to reach USD 131.39 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Central Nervous System Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Central Nervous System Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Central Nervous System Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AC Immune SA, Alkermes PLC, AstraZeneca PLC, Biogen Inc., Bristol-Myers Squibb Company, Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, H. Lundbeck A/S, Johnson & Johnson Private Limited, Lupin Limited, Merck KGaA, Novartis AG, Otsuka Pharmaceutical Co. Ltd, Pfizer, Inc., Shire PLC, Takeda Pharmaceutical Company Limited, TauRx Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd., and Wren Therapeutics Limited.

Market Segmentation & Coverage

This research report categorizes the Central Nervous System Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Diseases
- Cancer
- Degenerative Diseases
  - Alzheimer's Disease
  - Amyotrophic Lateral Sclerosis
  - Multiple Sclerosis
  - Parkinson's Disease
- Infectious Diseases
- Mental Health
  - Anxiety Disorders
  - Epilepsy
  - Psychotic Disorders
- Neurovascular Diseases
- Trauma
Drug Class
- Analgesics
- Anesthetics
- Anti-Epileptics
- Anti-Parkinson Drugs
- Antidepressant
- CNS stimulants
End-Users
- Hospitals
- Specialty Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

What is the market size and forecast of the Central Nervous System Therapeutics Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Central Nervous System Therapeutics Market?
What are the technology trends and regulatory frameworks in the Central Nervous System Therapeutics Market?
What is the market share of the leading vendors in the Central Nervous System Therapeutics Market?
Which modes and strategic moves are suitable for entering the Central Nervous System Therapeutics Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Central Nervous System Therapeutics Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of CNS disorders globally
5.1.1.2. Increasing approval of generic products due to patent expiration of key products
5.1.1.3. Increasing government fundings to improve healthcare infrastructure
5.1.2. Restraints
5.1.2.1. High cost of treatments
5.1.3. Opportunities
5.1.3.1. Advancements in diagnostics and therapeutics of CNS diseases
5.1.3.2. Ongoing R&D in pharmaceutical companies
5.1.4. Challenges
5.1.4.1. Strict & extended drug approval procedures
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Central Nervous System Therapeutics Market, by Diseases

6.1. Introduction
6.2. Cancer
6.3. Degenerative Diseases
6.4.1. Alzheimer's Disease
6.4.2. Amyotrophic Lateral Sclerosis
6.4.3. Multiple Sclerosis
6.4.4. Parkinson's Disease
6.4. Infectious Diseases
6.5. Mental Health
6.6.1. Anxiety Disorders
6.6.2. Epilepsy
6.6.3. Psychotic Disorders
6.6. Neurovascular Diseases
6.7. Trauma

7. Central Nervous System Therapeutics Market, by Drug Class

7.1. Introduction
7.2. Analgesics
7.3. Anesthetics
7.4. Anti-Epileptics
7.5. Anti-Parkinson Drugs
7.6. Antidepressant
7.7. CNS stimulants

8. Central Nervous System Therapeutics Market, by End-Users

8.1. Introduction
8.2. Hospitals
8.3. Specialty Clinics

9. Americas Central Nervous System Therapeutics Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Central Nervous System Therapeutics Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Central Nervous System Therapeutics Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. AC Immune SA
13.1.2. Alkermes PLC
13.1.3. AstraZeneca PLC
13.1.4. Biogen Inc.
13.1.5. Bristol-Myers Squibb Company
13.1.6. Eisai Co. Ltd.
13.1.7. Eli Lilly and Company
13.1.8. F. Hoffmann-La Roche AG
13.1.9. GlaxoSmithKline PLC
13.1.10. H. Lundbeck A/S
13.1.11. Johnson & Johnson Private Limited
13.1.12. Lupin Limited
13.1.13. Merck KGaA
13.1.14. Novartis AG
13.1.15. Otsuka Pharmaceutical Co. Ltd
13.1.16. Pfizer, Inc.
13.1.17. Shire PLC
13.1.18. Takeda Pharmaceutical Company Limited
13.1.19. TauRx Pharmaceuticals Ltd
13.1.20. Teva Pharmaceutical Industries Ltd.
13.1.21. Wren Therapeutics Limited
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET DYNAMICS
FIGURE 7. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2023 VS 2030 (%)
FIGURE 8. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 10. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 12. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 6. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 9. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 16. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANXIETY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHOTIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRAUMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 22. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANESTHETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTI-PARKINSON DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 29. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 47. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 48. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 49. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 50. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 52. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 53. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 54. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 55. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 74. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 75. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 76. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 77. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 79. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 80. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 81. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 82. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 87. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 89. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 90. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 91. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 92. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 97. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 102. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 107. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 112. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 117. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 119. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 120. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 121. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 122. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 123. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 127. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 135. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 136. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 137. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 138. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 140. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 141. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 142. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 143. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 145. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 146. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 147. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 148. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 150. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 151. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 152. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 153. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 154. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 155. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 156. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 157. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 158. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 163. ISRAEL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. ISRAEL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 165. ITALY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 166. ITALY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 167. ITALY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 168. ITALY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. ITALY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. NIGERIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 180. NORWAY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 181. NORWAY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 182. NORWAY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 183. NORWAY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 184. NORWAY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 185. POLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 186. POLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 187. POLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 188. POLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. POLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 190. QATAR CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 191. QATAR CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 192. QATAR CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 193. QATAR CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 194. QATAR CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 210. SPAIN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 211. SPAIN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 212. SPAIN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 213. SPAIN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. SPAIN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 218. SWEDEN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 219. SWEDEN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 225. TURKEY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 226. TURKEY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 227. TURKEY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 228. TURKEY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 229. TURKEY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 240. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 241. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 242. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET LICENSE & PRICING

Companies Mentioned

AC Immune SA
Alkermes PLC
AstraZeneca PLC
Biogen Inc.
Bristol-Myers Squibb Company
Eisai Co. Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
H. Lundbeck A/S
Johnson & Johnson Private Limited
Lupin Limited
Merck KGaA
Novartis AG
Otsuka Pharmaceutical Co. Ltd
Pfizer, Inc.
Shire PLC
Takeda Pharmaceutical Company Limited
TauRx Pharmaceuticals Ltd
Teva Pharmaceutical Industries Ltd.
Wren Therapeutics Limited

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	185
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 76.41 Billion
Forecasted Market Value ( USD ) by 2030	$ 131.39 Billion
Compound Annual Growth Rate	9.3%
Regions Covered	Global
No. of Companies Mentioned	21

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3263EUR$3,374USD£2,796GBP €3625EUR$3,749USD£3,107GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4133EUR$4,274USD£3,542GBP €4593EUR$4,749USD£3,936GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5004EUR$5,174USD£4,288GBP €5560EUR$5,749USD£4,765GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5874EUR$6,074USD£5,034GBP €6527EUR$6,749USD£5,594GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7615EUR$7,874USD£6,526GBP €8461EUR$8,749USD£7,251GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects

The report addresses key questions such as

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

CNS Therapeutics - Global Strategic Business Report

Global Central Nervous System Drugs Market by Drug Classes (Analgesics, Anesthetics, Anti-Epileptics), Diseases (CNS Trauma, Infectious Diseases, Mental Health), Drug Type, Distribution Channel - Forecast 2024-2030

Global Anti-Epileptic Drugs Market: Analysis By Drug Generation, By Distribution Channel, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028

Epilepsy Drugs Market by Generation Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Anti-Epileptics Drugs Type (Narrow-Spectrum AEDs, Broad-Spectrum AEDs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, and Others), and Region 2024-2032

Epilepsy Drugs Market Size and Forecasts 2020 - 2030, Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment, Distribution Channel, and Geography